Ohio University

A Dual-acting Chemo-preventive and Chemo-therapeutic Compound for UV-induced Carcinogenesis

Overview

According to the Skin Cancer Foundation, more than 3.3 million people are treated for non-melanoma skin cancer in the U.S. in 2012 and there will be more than 196,000 new cases of melanoma diagnosed in 2020. Approximately 90% of non-melanoma skin cancers and 86% of melanomas are associated with UV radiation from the sun1. Therefore, it is imperative that people take the necessary precautions to minimize their UV radiation exposure. The Skin Cancer Foundation recommends seeking shade, preventing sun burns, avoid tanning booths, covering up with clothing, and using adequate amounts of broad spectrum UVA/UVB sunscreen with an SPF 15 or higher every day and SPF 30 or higher for extended outdoor activities2.

UVA and UVB affect the skin, with UVA penetrating further
Image courtesy of Skin Cancer Foundation

Scientists at Ohio University have discovered a naturally occurring compound that is effective at inhibiting UV-induced skin cancer formation by reducing DNA damage. This compound may also be used as a chemoprevention measure due to its ability to sensitize pre-cancer cells to UV radiation, eliminating them before they become cancerous.

OU Ref: 16009 View PDF

Published Patent Application: US 2019/0388389 A1

References

1Skin Cancer Facts and Statistics. http://www.skincancer.org/skin-cancer-information/skin-cancer-facts

2Prevention. http://www.skincancer.org/prevention

Inventor

Dr. Shiyong Wu is a professor of chemistry and biochemistry in the College of Arts and Sciences at Ohio University. He has dedicated many years to studying cancer and ultraviolet light radiation. Other titles include reviewer of numerous journals such as Cancer Prevention Research and Cancer Chemotherapy and Pharmacology, as well as member of notable professional societies, including American Association of Cancer Research.